Page last updated: 2024-12-10

carboprostacyclin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

carboprostacyclin: potent stable prostacyclin analog which inhibits platelet aggretation; do not confuse with carboprost (15-methyl-PGF2alpha); RN given refers to (3aS-(2Z,3aalpha,4alpha(1E,R*),5beta,6aalpha))-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6436393
CHEMBL ID435828
CHEBI ID190588
SCHEMBL ID1479163
MeSH IDM0087386

Synonyms (44)

Synonym
BRD-K27499107-001-02-6
u-55185
carboprostacyclin
BSPBIO_001573
IDI1_034043
SPECTRUM5_001983
carbacyclin, >=90% (hplc)
NCGC00161296-03
NCGC00161296-01
NCGC00161296-02
6,9-methano pgi2
6,9-methanoprostaglandin i2
pentanoic acid, 5-((3as,4r,5r,6as)-hexahydro-5-hydroxy-4-((1e,3s)-3-hydroxy-1-octenyl)-2(1h)-pentalenylidene)-, (5e)-
9alpha-deoxy-9alpha-methylene-pgi2
6a-carba-pgi2
carba pgx
pentanoic acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-1-octenyl)-2(1h)-pentalenylidene)-, (3as-(2e,3aalpha,4alpha(1e,3r*),5beta,6aalpha))-
(5e)-6a-carba-prostaglandin i2
carbaprostacyclin
6,9-methano-pgi2
NCGC00161296-04
69552-46-1
HMS1989O15
BML1-G09
HMS1791O15
HMS1361O15
CHEMBL435828
CHEBI:190588
(5e)-5-[(3as,4r,5r,6as)-5-hydroxy-4-[(e,3s)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydro-1h-pentalen-2-ylidene]pentanoic acid
SCHEMBL1479163
BRD-K27499107-001-03-4
BRD-K27499107-001-05-9
XZFRIPGNUQRGPI-WBQKLGIQSA-N
6,9.alpha.-methylene-11.alpha.,15s-dihydroxy-prosta-5e,13e-dien-1-oic acid
HMS3402O15
carbacyclin (carbocyclic pgi2)
CS-0045198
HY-112322
SR-05000002106-2
sr-05000002106
(5e)-5-[(3as,4s,5r,6as)-5-hydroxy-4-[(e,3s)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydro-1h-pentalen-2-ylidene]pentanoic acid
cpgi
DTXSID801346736
AKOS040732707

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In contrast, PGD2 acted as a weak and partial inhibitor in guinea-pig platelet aggregation, producing a bell-shaped dose-response relationship."( Interaction of prostaglandin D2 with prostacyclin, carbacyclin and the hydantoin prostaglandin, BW245C, in guinea-pig platelets.
Hamid, S; Whittle, BJ, 1985
)
0.27
" A dosage of 2 ng/kg X min was tolerated by all patients."( [Treatment of Raynaud's phenomenon in scleroderma with a new stable prostacyclin derivative].
Gevatter, M; Hornstein, OP; Kaltenecker, A; Keller, J; Krais, T; Schönberger, A; Schricker, KT, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
prostanoidThe family of natural prostaglandins and prostaglandin-like compounds including prostacyclins and thromboxanes.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency70.79460.141337.9142100.0000AID1490
regulator of G-protein signaling 4Homo sapiens (human)Potency0.08500.531815.435837.6858AID504845
glucocerebrosidaseHomo sapiens (human)Potency28.18380.01268.156944.6684AID2101
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (144)

TimeframeStudies, This Drug (%)All Drugs %
pre-199048 (33.33)18.7374
1990's53 (36.81)18.2507
2000's31 (21.53)29.6817
2010's10 (6.94)24.3611
2020's2 (1.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (2.01%)5.53%
Reviews5 (3.36%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other141 (94.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]